Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Generic Drug Manufacturing Market Size, Share, Trends, and Forecast 2025-2034 | Patent Expirations and Biosimilars Drive 6.20% CAGR Toward USD 817.99 Billion

globenewswire.com
NVS Novartis AG is mentioned as a prominent company in the generic drug manufacturing market. The article discusses market growth drivers and trends, but does not provide specific sentiment towards Novartis.

Generic Drug Manufacturing Market Size, Share, Trends, and Forecast 2025-2034 | Patent Expirations and Biosimilars Drive 6.20% CAGR Toward USD 817.99 Billion Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -- "Generic Drug Manufacturing Market Size and Share Outlook: Forecast Trends and Growth Analysis Report (2025-2034)" has been added to ResearchAndMarkets.com's offering.

The global generic drug manufacturing market was valued at USD 448.23 billion in 2024 and is projected to reach USD 817.99 billion by 2034, expanding at a CAGR of 6.20% from 2025-2034. Growth is supported by rising demand for cost-effective medicines, patent expirations for branded drugs, expanding healthcare access in emerging economies, and the increasing prevalence of chronic diseases. Advances in pharmaceutical manufacturing technologies, supportive government initiatives, and regulatory pathways designed to accelerate approvals are also strengthening the market outlook.

Key Generic Drug Manufacturing Market Insights

Market Growth Drivers

Demand for affordable treatment options remains a primary driver of generic drug manufacturing market growth. Healthcare systems are increasing their use of generic and biosimilar medicines to reduce expenditure while expanding patient access to essential therapies. In September 2025, the Association for Accessible Medicines and the Biosimilars Council reported that generics and biosimilars delivered USD 467 billion in savings to the U.S. healthcare system in 2024. These products represented 90% of prescriptions but only 12% of total drug spending.

The growing global burden of cancer is also increasing demand for cost-effective oncology medicines. The World Health Organization projects more than 35 million new cancer cases by 2050, up 77% from approximately 20 million cases in 2022. Population growth, aging demographics, and changing exposure to risk factors are expected to increase the need for accessible cancer treatments, creating opportunities for generic oncology drug manufacturers.

Regulatory Collaboration and Manufacturing Developments

International regulatory cooperation is improving scientific alignment, quality standards, and approval processes. In June 2024, the U.S. FDA-led Generic Drug Cluster marked its third anniversary. The forum enables participating regulatory agencies to exchange knowledge, discuss policy developments, and coordinate best practices for generic drug development. Continued harmonization could support faster approvals and broader access to high-quality medicines across international markets.

Domestic production and supply chain resilience are receiving increased attention. In October 2025, the U.S. Food and Drug Administration announced an Abbreviated New Drug Application (ANDA) prioritization pilot intended to encourage U.S.-based testing and manufacturing. The initiative seeks to strengthen medicine supply chains, support product safety, and accelerate access to domestically manufactured generic drugs.

Therapeutic Area and Regional Outlook

Cardiovascular medicines are expected to retain a leading market position because of the substantial global burden of heart and circulatory diseases. The World Heart Federation reports that more than half a billion people are affected by cardiovascular conditions worldwide. These diseases caused 20.5 million deaths in 2021, accounting for nearly one-third of deaths globally. This burden continues to support demand for affordable cardiovascular treatments.

North America is expected to remain a major regional market, supported by established pharmaceutical infrastructure, favorable regulatory programs, high prescription volumes, and policies promoting domestic production. Europe and Asia Pacific also present significant opportunities, while improving healthcare access is supporting demand across Latin America and the Middle East and Africa.

Leading Generic Drug Manufacturers

Other prominent companies include Novartis AG, Fresenius Kabi, Lupin Group, Zydus Lifesciences, Gilead Pharma, and Glenmark. Competitive strategies include portfolio expansion, investment in complex generics and biosimilars, manufacturing upgrades, partnerships, collaborations, mergers, and acquisitions.

Generic Drug Manufacturing Market Segmentation

The generic drug manufacturing market forecast evaluates revenue growth, competitive positioning, funding activity, investment trends, unmet needs, regulatory challenges, and strategic initiatives. It also assesses how patent expirations, healthcare affordability priorities, manufacturing innovation, regulatory collaboration, and industry consolidation are shaping global market dynamics through 2034.

Key Attributes

For more information about this report visit https://www.researchandmarkets.com/r/2fnfb2

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.